Conceptualization and Scale Development of Excessive Emotional Behaviors
Development and Validation of the Excessive Emotional Behaviors Scale: Long and Short Forms Among Chinese Adults With Emotional Distress
Emotional disorders, including anxiety and depression, represent a major global health burden and are increasingly conceptualized within a transdiagnostic framework. Within this framework, emotional behaviors-defined as actions driven by attempts to regulate or control emotional experiences-are considered a central mechanism underlying the development and maintenance of emotional distress. Despite their theoretical importance in models such as the Unified Protocol (UP) and the Mindfulness Intervention for Emotional Distress (MIED), there is currently no dedicated, psychometrically validated instrument specifically designed to assess excessive emotional behaviors.
The present study aims to develop and validate a self-report scale of excessive emotional behaviors grounded in the theoretical frameworks of UP and MIED. Excessive emotional behaviors are conceptualized as behaviors whose frequency, intensity, or reliance exceeds adaptive levels in response to emotional experiences and contributes to functional impairment.
A mixed-method design will be employed. Study 1 will involve semi-structured cognitive interviews with approximately 18 participants experiencing anxiety or depressive distress to evaluate item clarity, experiential relevance, and content coverage, and to refine the initial item pool. Study 2 will consist of a quantitative survey with a larger sample to examine the scale's psychometric properties, including factor structure, reliability, and validity. Exploratory factor analysis (EFA) and confirmatory factor analysis (CFA) will be conducted to establish the underlying structure of the scale. Convergent and discriminant validity will be assessed through correlations with measures of experiential avoidance (AAQ-II, BEAQ), anxiety (GAD-7), and depression (PHQ-9).
The expected outcome is a brief, reliable, and valid instrument that captures multiple dimensions of excessive emotional behaviors, such as behavioral avoidance, cognitive avoidance, safety behaviors, and emotion-driven actions. This scale will provide a theoretically grounded and clinically useful tool for transdiagnostic research, mechanism testing, and intervention evaluation in emotional disorders.
調査の概要
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100871
- Peking University
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
Aged 18 years or older Current or recent experience of significant anxiety or depressive distress Adequate ability to understand and communicate in Chinese Able and willing to provide written informed consent
Exclusion Criteria:
Acute psychotic episode or other severe psychiatric disorder that would interfere with study participation Cognitive impairment that would prevent effective participation in the study
研究計画
研究はどのように設計されていますか？
デザインの詳細
コホートと介入
グループ/コホート |
|---|
|
General Adult Sample
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Initial Excessive emotional Behaviors Scale
時間枠：Baseline and 1 month
|
The Initial Excessive Emotional Behavior Scale (EEBS) consists of 40 items. Each item is rated on a 5-point scale, and the total score ranges from 40 to 200, with higher scores indicating more severe excessive emotional behavior and lower scores indicating fewer excessive emotional behaviors. Subscale scores are calculated as follows: Behavioral Avoidance: sum of Items 1-14 Cognitive Avoidance: sum of Items 15-21 Safety Signals: sum of Items 22-32 Emotion-Driven Behavior: sum of Items 33-40 The total EEBS score is obtained by summing all 40 items. Item 11 is reverse scored before computing the subscale and total scores. In addition to the total score, subscale scores may be analyzed separately to identify the individual's primary areas of difficulty. |
Baseline and 1 month
|
|
The Acceptance and Action Questionnaire-II (AAQ-II)
時間枠：Baseline and 1 month
|
The Acceptance and Action Questionnaire-II (AAQ-II) will be used to assess experiential avoidance and psychological inflexibility.
The scale contains 7 items, each rated on a 7-point Likert scale, with a total score ranging from 7 to 49.
Higher scores indicate greater experiential avoidance and psychological inflexibility, whereas lower scores indicate lower levels of experiential avoidance and greater psychological flexibility.
|
Baseline and 1 month
|
|
The Brief Experiential Avoidance Questionnaire (BEAQ)
時間枠：Baseline and 1 month
|
The Brief Experiential Avoidance Questionnaire (BEAQ) will be used to assess experiential avoidance across multiple domains.
The scale contains 15 items derived from the Multidimensional Experiential Avoidance Questionnaire (MEAQ).
With each item rated on a 6-point Likert scale, the total score ranges from 15 to 90.
Higher scores indicate greater experiential avoidance, whereas lower scores indicate lower levels of experiential avoidance.
|
Baseline and 1 month
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Generalized Anxiety Disorder Scale (GAD-7)
時間枠：Baseline and 1 month
|
The Generalized Anxiety Disorder Scale (GAD-7) will be used to assess anxiety symptoms.
The scale contains 7 items, each rated on a 4-point Likert scale, with a total score ranging from 0 to 21.
Higher scores indicate more severe anxiety symptoms, whereas lower scores indicate less severe anxiety symptoms.
|
Baseline and 1 month
|
|
Patient Health Questionnaire (PHQ-9)
時間枠：Baseline and 1 month
|
The Patient Health Questionnaire-9 (PHQ-9) will be used to assess depressive symptoms.
The scale contains 9 items, each rated on a 4-point Likert scale, with a total score ranging from 0 to 27.
Higher scores indicate more severe depressive symptoms, whereas lower scores indicate less severe depressive symptoms.
|
Baseline and 1 month
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- E20260416
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。